Latest News
Web Date: October 30, 2017

Kymera launches with $30 million to tackle targeted protein degradation

Backed by Atlas Venture, the firm hopes to put its first compound in the clinic in 2020
Department: Business
Keywords: Start-ups, Kymera, protein degradation, Arvinas

Kymera Therapeutics has launched with $30 million in funding from Atlas Venture, Lilly Ventures, and Amgen Ventures. The firm will develop bifunctional small molecules that it believes can tackle disease-causing proteins that have long stymied drug developers.

Kymera is the latest biotech company working on targeted protein degradation, a way of tagging troublesome proteins for the cellular trash bin.

Traditionally, small molecule drugs . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society